Boris Engels
16Patents
4h-index
56Co-inventors
59Inventor score
Filing activity: Dec 19, 2014 → Mar 27, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10287354B2 | Regulatable chimeric antigen receptor | Chemistry; Metallurgy | 21 | Active |
| US10525083B2 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | Chemistry; Metallurgy | 9 | Active |
| US10640569B2 | Human mesothelin chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 8 | Active |
| US10577417B2 | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | Chemistry; Metallurgy | 4 | Active |
| US11026976B2 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | Chemistry; Metallurgy | 2 | Active |
| US11413340B2 | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy | Human Necessities | 1 | Active |
| US12383601B2 | Chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12344651B2 | CD19 and CD22 chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11981731B2 | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | Chemistry; Metallurgy | 0 | Active |
| USRE49847E1 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | General | 0 | Active |
| US11975026B2 | CD19 and CD22 chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11578130B2 | Regulatable chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US11999794B2 | Human mesothelin chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US10189908B2 | Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants | Chemistry; Metallurgy | 0 | Active |
| US12186278B2 | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy | Human Necessities | 0 | Active |
| US11872249B2 | Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.